INTERNATIONAL AYURVEDIC MEDICAL JOURNAL



International Ayurvedic Medical Journal, (ISSN: 2320 5091) Volume 5, Issue 12, December, 2017

EFFECT OF ABHADI CHURNA AND MULAKA TAILA ON SANDHIGATA VATA WITH DIFFERENT METHODS

Gajendra Renuka¹, Khicharia Satyadev²

¹Lecturer Department of Swasthavritta and Yoga, ²Lecturer Department of Kayachikitsa, Shri N.P.A. Govt. Ayurved College, Raipur, Chhattisgarh, India

Email: gajendrarenuka@gmail.com

ABSTRACT

Sandhigata Vata is a most common disability disorder in all over the world, It is the disorder of bone and joints. Sandhigata Vata is a chronic degenerative disorder especially in old age groups. It causes pain in joints especially weight bearing joints. It makes life too difficult. Even, in everyday works, peoples feel disability due to pain. In modern science Sandhigata vata correlates with Osteoarthritis. It is a disorder, in which all joints becomes affected especially weight bearing joints. Sandhigata vata is a purely vatic vyadhi. The aim of this study is to evaluate the efficacy of Aabhadi Churna & Mulaka Taila in Sandhigata Vata in two groups. Patients attending to the O.P.D. & I.P.D. of Kayachikitsa from Pt. N. P. A. Govt. Ayurved collage and hospital, Raipur (C.G.) were randomly selected based on the clinical features. Group A (30 patients) were treated with internal use of Aabhadi Churna and Mulaka Taila and Abhyanga & Swadana with Mulaka Taila for two month. Group B (30 patients) were treated with only internal use of Aabhadi Churna and Abhyanga & Swedana with Mulaka Taila for two months. Though, the trial drug of Group A proves to be an effective remedy for Sandhigata Vata, because according to acharya Charak, Taila is best to shaman of vata dosha. It shows better efficacy than "Internal use of Aabhadi Churna and Abhyanga and Swedana with Mulaka Taila".

Keywords: Sandhigata Vata, Aabhadi Churna, Mulaka Taila, Abhyanga, Swedana

INTRODUCTION

In Ayurveda, Vata is explained as life and vitality, supporter of the all embodied beings and sustains long life free of disorders. In Tridoshas, Vata and Kapha plays an important role in Sandhigata Vata. Sandhigata Vata is the im-

balance or vitiation of *Vata* and this vitiated *Vata* disturbs the normal state of the *Kapha* in all the joints.

Vayu regulates all the functions of the body and keeps all the *dhatus* in their physiological limits

and also promotes that, they works properly. In Sandhigata Vata, vata becomes vitiated when different Vata prakopaka nidana are taken and this vitiated Vata, desiccates Shleshka Kapha in the Sandhi and it results in difficulty in movement of the joints and causes their degeneration. Sandhigata Vata is the most common joint disorder of older age group in all countries. Vata controls all the activities of the body in every stage of life, but in old age vata becomes more aggravated and causes Dhatushoshana, which results all *Dhadus* of the body undergoes *kshva*. Sandhigata Vata is a vyadhi of Vriddhavastha but todays lifestyle is responsible for its increased incidence in young age groups. This disease affects the patients for prolonged period causing loss of function as well as deformity of the joint especially weight bearing joints like knee joints. The abnormalities in Sandhis by Prakupita Vata are the main cause in samprapti of Sandhigata Vata. Sandhis come under the madhyama roga marga and thus, involvement of Madhyama Roga Marga, vata dosha and dhatukshaya, makes the disease kashta sadhya. Sandhigata Vata is described under vata vyadhi in all ancient literatures. There is no any separate reference of Sandhigata Vata. The shortest description of this disease is available in Charak Samhita, Sushruta Samhita and Ashtangahridaya etc. The later authors explained the clinical aspect of this disease in the wordings of Charaka and Sushruta. Acharya Charaka was the first person who described the disease separately naming it "Sandhigata Anila", but has not been included under the 80 types of Nanatmaja Vyadhi Cha.Chi.(28/37) as described by him. Acharya Vagabhatta has also considered Vata Vyadhi as a Maharoga.

"India is likely to notice an endemic of osteoarthritis with about 80% of the 65+ popula-

tion in the country suffering with wear and tear of joints. 40% of these people are likely to suffer from severe Osteoarthritis, which will disable them from daily activities, say the experts quoting the World Health Organisation." (WHO)

In all Samhitas, treatment of Sandhigata Vata is almost same. A common treatment for Vata Vyadhi has been described by Acharya Charaka i.e. repeated use of Snehana, Swedana, Basti and Mriudu Virechana. Acharya Sushruta has mentioned the treatment for Sandhigata Vata clearly i.e. Snehana, Upanaha, Agnikarma, Bandhana and Unmardana.

Taking reference from ancient classics, *Vatahara Churna*, local *Abhyanga* and *swedana* are selected for this study.

During this study, in Group A - Aabhadi churna and Mulaka Taila was used internally along with Abhyanga and Swedana of Mulaka Taila. In Group B - Aabhadi churna was given internally along with Abhyanga and Swedana of Mulaka Taila.

AIMS AND OBJECTIVES

To evaluate the efficacy of internal use of *Aabhadi Churna & Mulaka Taila* with *Abhyanga* and *nadi swedana* and only internal use of Aabhadi Churna with *Abhyanga* and *nadi swedana* in *Sandhigata Vata*.

MATERIALS AND METHODS

Patients attending to the O.P.D. & I.P.D. of *Kayachikitsa* from Pt. N. P. A. Govt. Ayurved collage and hospital, Raipur (C.G.) were randomly selected based on the clinical features and a detailed research Proforma was made to observe the clinical features and disease pathology. The study was exclusively based on clinical trials.

STUDY DESIGN

Group A:

- Patients were treated by internal use of Aabhadi Churna and *mulaka Taila*.
- Local Abyanga with Mulaka Taila + Nadi swedana

Group B:

• Patients were treated by internal use of *Aabhadi Churna*.

• Local Abyanga with Mulaka Taila + Nadi swedana

Posology:

- Aabhadi Churna 5 gm / BD, With Ushnodaka (after meal)
- Mulaka Taila 10 ml / OD , With Milk (morning)
- *Abhyanga* + *Swedana* QS

Study duration: 60 days (2 month)

COMPOSIT	ION OF <i>AABHADI CHUR</i>	VA				
Ingredients, botanical name, quantity use in Aabhadi Churna:						
(Yog. K	Rat. Vatavyadhi Chi. 1-5)					
1. Aabha	Acasica arabica	1 part				
2. Rasna	Plucha lansiolata	1 part				
3. Guduchi	Tinospora cardifolia	1 part				
4. Shatavari	Asparagus recemosa	1 part				
5. Shunthi	Gingeber officinalis	1 part				
6. Shoufa	Anethum sowa	1 part				
7. Aswagandha	Withenia sominifera	1 part				
8. Hrivera	juniperous communies	1 part				
9. <i>Vidhara</i>	Argyrea speciosa sweet	1 part				
10.	Roxburghiamum ammi	1 part				
11. Ajmoda	Apium graveolens	1 part				

COMPOSITION OF MULAKA TAILA –

Cha.Chi. (28/136,137)

Ingredients, quantity:

4. Lavana

5. Ardraka

6. Shunthi

_		
1.	Juice of radish	
2.	Milk	3 Prastha
3.	Curd	
4.	Tila Taila	1 prastha
Kalka	dravya:	
1.	Madhuyasti	1 pala
2.	Sharkara	1 pala
3.	Rasna	1 pala

1 pala

1 pala

1 pala

SELECTION OF PATIENT

Patients having following symptoms in any joint:

- Sandhishoola (Pain)
- Sandhishotha (Swelling)
- Prasarana Akunchanajanya vedana (Pain during flexion and extention)
- Sparsha Asahyata (Tenderness)
- Sandhi Sphutana (Crepitus)
- Sandhi Graha (Stiffness)

Criteria for Inclusion:

- Patient between 40 years to 60 years of age.
- Patients presenting with classical sign and symptoms of *Sandhigata Vata*.

Criteria for Exclusion:

- Patients below 40 year and above 60 year of age.
- Pregnant women and lactating mother.
- Associated with simple or compound fractures.
- Associated with trauma.
- Associated with other systemic or metabolic disorder.
- Patients of *Aamvata*, *Vatarakta* and diabetes are excluded.
- Patients on steroid therapy.
- Patients who have undergone surgery.

CRITERIA FOR ASSESSMENT

To assess the effect of therapy, all the signs and symptoms were given scoring depending upon their severity which is as follows:

1. Sandhishula (Pain):

- "No pain No pain in the joints" 0
- "Mild pain Pain complained but tolerable"
 1
- "Moderate pain Pain complained and disturbs routine work" 2
- "Severe difficulty in working and completely interrupting routine work" 3

2. Sandhishotha (Swelling):

- "No swelling" -0
- "Mild swelling Feeling of swelling with heaviness of joints" 1
- "Moderate apparent swelling" 2

• "Severe - Huge swelling" – 3

3. Akunchana Prasaranjanya Vedana

- "No pain Absence of movement restriction" 0
- "Pain without winching of face" − 1
- "Pain with winching of face" 2
- "Does not allow passive movements" − 3

4. Sandhi Sphutana (Crepitus)

- "NO Absence of crepitus" 0
- "Mild Perception on touch" 1
- "Moderate Audible on attention" 2
- "Severe Clearly audible" 3

5. Sparsha Asahyata (Tenderness)

- "Nil No tenderness" 0
- "Mild patient says tenderness" 1
- "Moderate Winching of face on touch" 2
- "Does not allow to touch the joint" -3

6. Sandhigraha (Stiffness)

- "No Stiffness No morning stiffness" 0
- "Mild Morning stiffness of 5-10 minutes duration" 1
- "Moderate Morning stiffness of 10-15 minutes duration" 2
- "Severe morning stiffness of 15-30 minutes duration" – 3

TOTAL EFFECT OF THERAPY

Complete Remission: 100%

Maximum Improvement:>75 to <100%</th>Moderate improvement:>50 to 75%Mild improvement:>25 to 50%No improvement:0-25%

Chief complaints wise distribution of 60 patients of Sandhigata Vata

	-	_	9	
S. No.	Chief Complaints		Number of patients	Total

		Group A	Group B	
1.	Sandhishoola	30	30	60
		100%	100%	100%
2.	Sandhishotha	30	30	60
		100%	100%	100%
3.	Akunchan Prasara Janya Vedna	28	30	58
		93.3%	100%	96.7%
4.	Sandhi Sphutan	25	26	51
		83.3%	86.7%	85.0%
5.	Sparsha-Asahyata	24	23	47
		80.0%	76.7%	78.3%
6.	Sandhigraha	30	30	60
		100%	100%	100%

In this study, all the patients (100%) were having Sandhi Shoola, Sandhishotha and Sandhi Graha. Akunchana Prasarana Janya Vedana

was present in 96.7% patients, *Sandhi Sphutan* was present in 85.0% patients and *Sparsha-Asahyata* was present in 78.3% patients.

EFFECT OF THERAPY (GROUP – A)

Table 33: Effect of Chief complaints in the patients of Sandhigata Vata:

S.	Chief complaints	Mean		Mean Dif-	% of	S. D.	S. E.	t-value	p-value	Remarks
No.				ference						
		BT	AT		Relief					
1.	Sandhishoola	1.90	0.43	1.47	77.38	0.507	0.093	15.832	0.000	H.S.
2.	Sandhishotha	1.93	0.40	1.53	79.27	0.507	0.093	16.551	0.000	H.S.
3.	Akunchan Prasarana Vedana	1.70	0.60	1.10	64.71	0.728	0.130	8.462	0.000	H.S.
4.	Sandhi Sphutan	1.70	0.57	1.13	66.47	0.730	0.133	8.500	0.000	H.S.
5.	Sparsha Asahyata	1.57	0.43	1.13	71.97	0.937	0.171	6.624	0.000	H.S.
6.	Sandhigraha	1.83	0.53	1.30	71.04	0.702	0.128	10.14	0.000	H.S.

EFFECT OF THERAPY (GROUP - B)

Table 37: Effect of Chief complaints in the patients of Sandhigata Vata

S.	Chief complaints	Mean		Mean	% of	S. D.	S. E.	t-value	p-value	Remarks
No.		BT	AT	Difference	Relief					
1.	Sandhishoola	1.90	0.43	1.47	77.37	0.819	0.150	9.805	0.000	H.S.
2.	Sandhishotha	1.90	0.47	1.43	75.26	0.728	0.133	10.785	0.000	H.S.
3.	Akunchan Prasarana Vedana	1.97	0.57	1.40	71.07	0.724	0.132	10.592	0.000	H.S.
4.	Sandhi Sphutan	1.60	.53	1.07	68.88	0.583	0.106	10.016	0.000	H.S.
5.	Sparsha Asahyata	1.47	0.43	1.04	70.75	0.890	0.162	6.360	0.000	H.S.
6.	Sandhigraha	1.97	0.53	1.44	73.10	0.679	0.124	11.564	0.000	H.S.

TOTAL EFFECT OF THERAPY (GROUP A)

Gradation	No. of Patients	%
Complete Remission (100%)	1	3.33
Maximum Improvement (>75 to <100%)	9	30.0
Moderate Improvement (>50 to 75%)	17	56.66
Mild Improvement (>25 to 50%)	3	10.0
No Improvement (0 to 25%)	0	0.0

In group A, out of 30 patients, 3.33% patients achieved complete remission, while 30.0% patients found in maximum improvement and

56.66% were having moderately improvement and 10.0% patients found mild improvement.

(GROUP B)

Gradation	No. of Patients	%
Complete Remission (100%)	1	3.33
Maximum Improvement (>75 to <100%)	5	16.66
Moderate Improvement (>50 to 75%)	23	76.66
Mild Improvement (>25 to 50%)	1	3.33
No Improvement (0 to 25%)	0	0.0

In group B, out of 30 patients, 3.33% patients achieved complete remission, while 16.66% patients found in maximum improvement and 76.66% were having moderately improvement and 3.33% patients found mild improvement.

DISCUSSION

Sandhigata Vata is a most common disease in old age groups in all over the world. Sandhigata Vata is described in all Samhita and Sangraha Grantha as a separate clinical entity under the heading of Vata vyadhi. It is not included in 80 types of Nanatmaja Vatika Vikara by Acharya Charaka. But, Vata Khudata is one of the Nanatmaja Vata Vikara mentioned by Acharya Charaka. Further in the list of Kashta Sadhya Vata Vyadhi the name of Khuda Vata has been stated. While commenting onward "Khudavata", Chakrapani explains the meaning of Khudavata as a "Gulpha Vata" or Sandhigata Vata. Hence, it can be said that according to

Chakarapani, Sandhigata Vata is the Nanatmaja Vata Vikara. It is characterized by Sandhishoola, Sandhishotha, Sandhigraha etc.

In the present clinical study 60 patients with the complaints of Sandhishoola, Sandhishotha, Prasarana Akunchanajanya vedana, Sparsha Ashyata, Sandhi Sphutana and Sandhi Graha etc. attending OPD and IPD Patients of Pt. N. P. A. Govt. Ayurvedic collage and hospital, Raipur (C.G.) were randomly selected into two groups. 30 patients were treated with internal use of Aabhadi Churna and Mulaka Taila and Abhyanga & Swadana with Mulaka Taila for two month. 30 patients were treated by Internal use of Aabhadi Churna and Abhyanga & Swedana with Mulaka Taila for two months.

Sandhishoola, sandhishotha and Sandhigraha was found in 100% of cases. In Sandhigata Vata there will be aggravation of Vata Dosha which is responsible for any kind of Shoola Pradhana

Vedana. Akunchana Prasaranajanya Vedana was found 96.7% of patients which also occurs aggravation of Vata Dosha and Kaphakshaya. Sandhi sphutana was found in 85.0% of patients. Sparsha Asahyata was found in 78.3% patients that also due to aggravation of Vata.

In group A, 3.33% patients achieved Complete remission, while 30.0% patients obtained Maximum improvement, whereas 56.66% Moderate improvement and 10.0% gets mild improvement was also reported.

In group B, 3.33% patients achieved complete remission whereas 16.66% patients had maximum improvement, while moderate improvement was found in 76.66% patients and 3.33% patients got mild improvement.

In this clinical research work, no patient observed in unchanged condition, every patient gets relief either less or more.

The above mentioned data shows that Internal use of *Aabhadi Churna* and *Mulaka Taila* along with local *Abhyanga* and *Swedana* of *Mulaka Taila* i.e. group A has provided better relief in the disease *Sandhigata Vata* (Osteoarthritis) in the present study. Though, the results of both groups proved to be highly effective and also statistically highly significant in different parameters. The result of Group A was better may be due to the following causes-

Group A patients were treated both drugs internally. In this group pana of Mulaka Taila is works best because at the condition of taila pana, taila reaches into dhatu much faster than external application. Abhyanga and swedana of Mulaka Taila leads to vasodilatation of local area which facilitates increased blood supply. As a result joints get more nourishment and its primary and accessory structure become strengthen and helps in early recovery. At the same time increased circulation provides dis-

carding of the local tissue metabolic waste product, helps in tissue rejuvenation and thus promote early recovery.

PROBABLE MODE OF ACTION OF AAB-HADI CHURNA

In Yogaratnakar Aacharya mentioned Aabhadi Churna in Vatavyadhi chikitsa and indicates for all types of Vatavyadhi so it is also treated Sandhagata Vata. Drugs of Aabhadi Churna Works in Sandhigata Vata in different facts which is mentioned below:

a. In Dosha -

All the drugs of Aabhadi Churna is having mainly Ushna virya and Kapha-Vata shamaka property. This Ushna virya vitiates the Sheeta guna of Vayu and breaks samprapti of Sandhigata Vata so further process of disease diminishes.

Vata-kaphaja aahara – vihara is main cause of Sandhigata Vata and doshakarma of trial drugs is mainly Kapha-vata shaman, so there is also found Samprapti vighatana in dosha leval.

b. In Dhatvagni –

Some drugs have *Laghu*, *Tikshna guna* and *Ushna Virya*, will act as *deepana* and *pachana* in action, which help in *samprapti vigatana* of *sandhigata Vata*, and does *srotoshodhana*. Make a good quality of Rasa *dhatu* and further *dhatu* also make in proper way which helps to cure the disease.

c. In Vayu and Dhatukshya -

Sandhigata Vata is a disease of Vriddhavastha and in this stage of life more dhatukshya occurs. Some ingredients such as Ashwagandha, Shatavari, Guduchi are acts as Rasayana. This is very helpful in the management of Sandhigata Vata in which the dhatu kshaya is the main symptom and also acts as Vayah sthapana.

Some drugs are *Vedana sthapana* and *Shoola prashmana* like *Ashvagandha, Guduchi, Hrivera, Ajamoda, Yavani* and cures the main symptom of *Sandhigata Vata* which is *Sandhishoola*.

PROBABLE MODE OF ACTION OF MU-KALA TAILA

Drugs used in Mulaka Taila are Tila taila, Dudgha, Dadhi, Mulethi, Sharkara, Rasna, Saindhva lavana, Aardraka and Shunthi.

Main drug of Mulaka Taila is Mulaka, which is Ushna virya, Tridoshahara and works as deepana-pachana. Dudgha and Dadhi are snigdha guna, which mitigate the Rooksha guna of Vayu. Aardraka and Shunthi are Tikshna and works as deepana-pachana, shoolahara, shrotoshodhaka and shothahara. This tikshna guna of drugs breaks the Samprapti and cures aavarana janya Sandhigata Vata.

In *Pana* and *Abhyanga* of *Mulaka Taila* both condition *Saindhva lavana* acts as mediator which dissolves the drug and reaches the *taila* in *sukshma srotasa*. (Acts as *Yogavahi*)

CONCLUSION

- Sandhigata Vata is a disease of Vriddhavastha.
- According to the literary profile, this disease is *Asadhya* or incurable in nature, this is also supported by the recurrence of same type of complaint in the patient included in the present clinical study. The medication can give only symptomatic relief for certain period.
- In age of 40, some patients have very good response after treatment and in these patients found less recurrence.
- Though the trial drug of the present clinical study that is "Internal use of Aabhadi

- Churna and Mulaka Taila, Abhyanga and Swedana with Mulaka Taila" proves to be an effective remedy for Sandhigata Vata. It shows better efficacy than "Internal use of Aabhadi Churna and Abhyanga & Swedana with Mulaka Taila".
- The present study, the size of sample was small and period of study was limited. Hence it is difficult to draw a definite conclusion regarding this study. In this context, it is suggested that the study should be continued with large sample and treatment for longer duration.
- It is expected that the present study will disclose some definite clues to the future researchers.

REFERENCES

- Agnivesha, Charaka samhitha(poorvardha), vidyotini hindi commentary, by Pt. Rajeshwarddatta Shastri, Chaukhambha Bharti Academy, Varanasi.
- Agnivesha, Charaka samhitha (Uttarardha), vidyotini hindi commentary, by Pt. Rajeshwarddatta Shastri, Chaukhambha Bharti Academy, Varanasi.
- Agnivesha, Charaka samhitha (Purvardha), vidyotini hindi commentary, by Pt. Rajeshwarddatta Shastri, Chaukhambha Bharti Academy, Varanasi.
- 4. Sushruta, Sushruta samhita, (purvardha) Chikitsa, by Kaviraj Dr. Ambikadutta Shastri, Chaukhambha Sanskrit samsthan Varanasi.
- Vagbhata, Astanga Hridaya, Sutra sthana, "Nirmala" hindi commentary, by Dr. Bramhanand Tripathi, Chaukhambha sanskrit pratishthan.

- 6. Introduction to Kayachikitsa, by C. Dwarakanatha, Chaukhambha Orientalia, Varannasi.
- Yogaratnakara Vatavyadhinidana Vatavyadhichikitsa, Vaidya Lakshmipatisastry editor. Varanasi: Chaukhambha Sanskrit Sansthan.
- 8. Dravyaguna vijnana, vol.-2 (Vegetable drugs), Prof. P.V. Sharma, Chaukhambha bharti academy, Varanasi.
- 9. Dravya guna vijnana, vol-2, Dr. J. L. N. Sastry, foreword by, Prof. K. C. Chunekar, Chukhambha orientalia, Varanasi.

Source of Support: Nil Conflict Of Interest: None Declared

How to cite this URL: Gajendra Renuka & Khicharia Satyadev:Effect Of Abhadi Churna And Mulaka Taila On Sandhigata Vata With Different Methods. International Ayurvedic Medical Journal {online} 2017 {cited December, 2017} Available from:

http://www.iamj.in/posts/images/upload/4313 4321.pdf